# PROMISE V2 and miTNM (PSMA PET staging framework)

Source: https://onco.cc/terms/promise-mitnm/  
OnCo record `promise-mitnm` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PROMISE V2 is a standard way to read and report PSMA PET scans in prostate cancer, describing where the cancer is with a molecular-imaging version of TNM (miTNM) and tracking change in trials.

## Summary

The prostate cancer molecular imaging standardized evaluation (PROMISE) criteria describe disease extent on PSMA PET as molecular imaging TNM. PROMISE V2 (Seifert and colleagues, European Urology 2023) updates miTNM, improves assessment of local disease, slightly modifies the PSMA-expression score, and adds a framework of parameters to record over time in clinical trials, which can feed PSMA PET progression (PPP) or RECIP. A low PSMA-expression score predicted shorter survival after lutetium-177 PSMA therapy in the studies reviewed.

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: PROMISE V2; PROMISE criteria; miTNM; molecular imaging TNM; PSMA-expression score

## Sources

- Seifert et al., Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework including response evaluation for clinical trials (PROMISE V2) (Eur Urol 2023): https://doi.org/10.1016/j.eururo.2023.02.002

## Connected records

- terms: [Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)](https://onco.cc/terms/staging-systems/), [PSMA PET progression and response consensus (PPP)](https://onco.cc/terms/psma-pet-response-criteria/), [PSMA-RADS (PSMA PET reporting system)](https://onco.cc/terms/psma-rads/), [RECIP 1.0 (PSMA PET response in prostate cancer)](https://onco.cc/terms/recip-1/), [TNM staging](https://onco.cc/terms/tnm-staging/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [PSMA PET](https://onco.cc/technologies/psma-pet/)

---
JSON: https://onco.cc/api/v1/entities/promise-mitnm.json